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ABSTRACT
Although long-term exposure to nicotine is highly addictive, one
beneficial consequence of chronic tobacco use is a reduced risk for
Parkinson’s disease. Of interest, these effects both reflect structural
and functional plasticity of brain circuits controlling reward and
motor behavior and, specifically, recruitment of nicotinic acetylcho-
line receptors (nAChR) in mesencephalic dopaminergic neurons.
Because the underlying cellular mechanisms are poorly understood,
we addressed this issue with use of primary cultures of mouse
mesencephalic dopaminergic neurons. Exposure to nicotine (1–10
mM) for 72 hours in vitro increased dendritic arborization and soma
size in primary cultures. These effects were blocked by mecamyl-
amine and dihydro-b-erythroidine, but not methyllycaconitine. The
involvement of a4b2 nAChR was supported by the lack of nicotine-
induced structural remodeling in neurons from a4 null mutant mice
(KO). Challenge with nicotine triggered phosphorylation of the
extracellular signal-regulated kinase (ERK) and the thymoma viral
proto-oncogene (Akt), followed by activation of the mammalian
target of rapamycin complex 1 (mTORC1)-dependent p70 ribo-
somal S6 protein kinase. Upstream pathway blockade using the
phosphatidylinositol 3-kinase inhibitor LY294002 [2-(4-morpholinyl)-
8-phenyl-4H-1-benzopyran-4-one hydrochloride] resulted in sup-
pression of nicotine-induced phosphorylations and structural
plasticity. These effects were dependent on functional DA D3
receptor (D3R), because nicotine was inactive both in cultures
from D3R KO mice and after pharmacologic blockade with D3R
antagonist trans-N-4-2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-
2-yl)ethylcyclohexyl-4-quinolinecarboxamide (SB-277011-A)
(50 nM). Finally, exposure to nicotine in utero (5 mg/kg/day for 5
days) resulted in increased soma area of DAergic neurons of
newborn mice, effects not observed in D3 receptor null mutant
mice mice. These findings indicate that nicotine-induced
structural plasticity at mesencephalic dopaminergic neurons
involves a4b2 nAChRs together with dopamine D3R-mediated
recruitment of ERK/Akt-mTORC1 signaling.
Introduction
Tobacco smoking is a pervasive habit that has been associated
with pathologic addiction (Benowitz 1988) and reduced risk for
Parkinson’s disease (PD) (Grandinetti et al., 1994; Wirdefeldt
et al., 2011). Of interest, in both conditions, a critical substrate
was recognized to be the DAergic system, involving neurons
located in the ventral tegmental area (VTA) (Corrigall et al.,
1994) and the substantia nigra (SN) (Quik et al., 2006), respec-
tively. Although an impressive amount of neuropharmacological
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studies was dedicated to the effect of nicotine on the mes-
encephalic DAergic system, comparatively little research has
focused on morphologic remodeling and structural plasticity.
Of interest, morphologic remodeling was found with other
addictive drugs, including psychostimulants (Nestler et al.,
1993; Mueller et al., 2006; Sarti et al., 2007). Using primary
culture from mouse embryo, we recently showed that exposure
to amphetamine and cocaine produced structural plasticity in
vitro by increasing dendrite number, maximal dendrite length,
and soma area of mesencephalic DAergic neurons (Collo et al.,
2008, 2012). These effects were conditional on functional dopa-
mine D3 receptor (D3R), a 7-transmembrane receptor (Missale
et al., 1998) implicated in the reinforcing properties of psychos-
timulants and nicotine (Heidbreder et al., 2005; Le Foll et al.,
2007). Of interest, similar structural plasticity was produced by
D3R-preferential DAergic agonists (Van Kampen and Eckman,
2006; Collo et al., 2008), agents currently used for PD treatment
(Joyce and Millan, 2007).
The evidence for neurotrophic effects of nicotine is not un-
precedented. Nicotine exposure attenuates the damage pro-
duced by nigrostriatal pathway lesions and fosters regeneration
of the DAergic system (Janson et al., 1988a,b; Quik et al., 2006).
More recently, transcriptional profiling in VTA showed that
nicotine regulates 47 genes involved in neuronal morphogen-
esis (Doura et al., 2010). Nicotine exerts its effects by binding
to the nicotinic acetylcholine receptors (nAChRs), transmem-
brane pentameric oligomers consisting of different combina-
tions of 9 a-subunits and 3 b-subunits (Changeux, 2010). In
DAergic neurons, the main functional receptors are a4b2
nAChRs that play a primary role in controlling DA release,
neuronal firing, and nicotine-induced behavior (Picciotto
et al., 1998; Marubio et al., 2003; Changeux, 2010).
In this article, we investigated the structural remodeling
effects of nicotine in mesencephalic DAergic neurons by study-
ing the morphologic changes produced by nicotine in an es-
tablished protocol of primary neuronal cultures from mouse
embryo (Collo et al., 2008, 2012). Pharmacologic antagonists
and neuronal cultures derived from mice carrying a4 nAChR
subunit or D3R gene knockout (KO) mutation were used to
dissect the critical components of structural plasticity pro-
duced by nicotine. Because a large body of evidence involves
phosphorylation of extracellular signal-regulated kinase (ERK)
and thymoma viral proto-oncogene (Akt) in dendrite out-
growth and soma size increase via activation of the mamma-
lian target of rapamycin (mTOR) (Kwon et al., 2003; Jaworski
et al., 2005; Kumar et al., 2005), we extended our exploration
of nicotine’s role to these intracellular pathways. To confirm
the relevance in vivo of these observations, we studied the
morphologic effects of nicotine on the DAergic system of new-
born mice exposed in utero at the same embryonic stage used
for the in vitro cultures.
Materials and Methods
Chemicals. (-)-Nicotine ditartrate, mecamylamine, dihydro-
b-erythroidine (DHbE), methyllycaconitine (MLA), 7-hydroxy-N,N-
di-propyl-2-aminotetralin (7-OH-DPAT), sulpiride, (R)-(1)-7-chloro-8-
hydroxy-3-methyl–1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
hydrochloride (SCH23390), rapamycin, 2-(4-morpholinyl)-8-phenyl-
4H-1-benzopyran-4-one hydrochloride (LY294002), and 2-(2-amino-3-
methoxyphenyl)-4H-1-benzopyran-4-one (PD98059) were purchased
from Tocris Bioscience (Bristol, UK); brain-derived neurotrophic factor
(BDNF) was from Alomone Laboratories Ltd. (Jerusalem, Israel); and
SB-277011-A was a gift from C. Heidbreder, GlaxoSmithKline (Verona,
Italy). Nicotine,mecamylamine, DHbE,MLA, 7-OH-DPAT, SCH23390,
and BDNFwere dissolved in water; SB-277011-A, rapamycin, PD98059,
and LY294002 were dissolved in dimethylsulfoxide (.1:3000 final
dilution), while sulpiride was dissolved in ethanol (.1:2000 final
dilution), all as recommended by producer. For each control treat-
ment, the vehicle was prepared with the respective dilution of
dimethylsulfoxide or ethanol.
Animals. CD1 mice were obtained from Charles River Laborato-
ries (Calco, Italy). The following knockout mice were used: mice
genetically deprived of dopamine D3R (D3KO) from the Jackson
Laboratory (Bar Harbor, ME) (B6.129S4-Drd3Tm1Dac/J) (Accili et al.,
1996) and mice genetically deprived of a4 subunit of nAChR (a4KO)
(Marubio et al., 2003). As control, C57BL6/J singenic mice were used.
Breeding of all mice was performed to achieve timed pregnancy
with the accuracy of 6 0.5 days. The embryonic day (E) was deter-
mined by considering the day of insemination (determined by vaginal
plug) as day E0.5. Animal care was in accordance with the European
Communities Council Directive of November 24, 1986 (86⁄609⁄ EEC),
and in line with Italian law.
Primary Mesencephalic Cultures. Primary mesencephalic cul-
tures were prepared as described in Collo at al. (2008). In brief,
ventral mesencephalon tissues were dissected from E12.5 mouse
embryos (sex unknown) and collected in ice-cold Hanks’ buffered
salt solution (EuroClone, Milan, Italy). Tissues were transferred in
Accumax (Sigma-Aldrich, St. Louis, MO), mechanically dissociated
at room temperature, and resuspended in Neurobasal medium [Gibco
(Invitrogen), Carlsbad, CA] containing 2 mM glutamine (EuroClone)
and B27 supplement [Gibco (Invitrogen)]. Cells were counted, seeded
on poly-D-lysine⁄ laminin- (Sigma-Aldrich) coated coverslides (5  104
cells/ml) or 12-well plates (5  105 cells/ml), and cultured at 37°C in
a humidified atmosphere of 5%CO2 and 95% air. No fetal bovine serum
was added to the cultures; 50% of the medium was changed every two
days until treatment. Under these conditions, the cultures contained
.99.5% neurons and ,0.5% astrocytes, as assessed by microtubule-
associated protein 2 and glial fibrillary acidic protein immunostaining,
respectively (unpublished data). Pharmacological treatments were
conducted in vitro after 5 days from seeding, time required for primary
culture stabilization.
In Vivo Prenatal Nicotine Treatment. Pregnant D3KO and
singenic wild-type mice were individually housed in a climate-controlled
room on a 12/12-hour light/dark cycle with ad libitum access to food
and water. Treatments were performed during the light period (9:00 AM–
6:00 PM). All mice were weighed daily starting at day 10. At day 12.5,
pregnant mice weighing 25–30 g were administered intraperitoneally
with two daily doses of 5 mg/kg nicotine or saline as described by Vezina
et al. (2007). Treatments were repeated for 5 days, from E12.5 through
E17. After each injection, animals were placed for 30 minutes in a clean
cage and inspected for locomotor activity. After delivery, P1 newborn
mice (sex unknown) were sacrificed, and the brains were removed and
processed for immunohistochemistry.
Immunocytochemistry and Immunofluorescence in Pri-
mary Cultures. Immunocytochemistry and immunofluorescence
were performed as described in Collo et al. (2012). In brief, for immu-
nocytochemistry, mesencephalic neurons were fixed in phosphate-
buffered saline (PBS) containing 3% paraformaldehyde⁄3% sucrose
(both Sigma-Aldrich); blocked in PBS containing 0.3%Triton (Promega,
Madison,WI), 1% normal goat serum (Jackson ImmunoResearch,West
Grove, PA), and 5% bovine serum albumin (BSA; Sigma-Aldrich);
and incubated overnight at 4°C with a rabbit polyclonal anti-
tyrosine hydroxylase (TH) antibody (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA), followed by a biotinylated goat anti-rabbit antibody
(Jackson ImmunoResearch; 30 minutes at room temperature) and
a final incubation with avidin-biotinylated horseradish peroxidase
complex (ABC; Vector Laboratories, Burlingame, CA). Color develop-
ment was achieved by addition of 3,39diaminobenzidine (Sigma-
Aldrich) for 45 seconds. To study the expression of phosphorylated
ERK (p-ERK1/2) or Akt (p-Akt(Thr308)) in dopaminergic neurons,
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mesencephalic cultures were fixed with methanol and incubated with
a rabbit polyclonal antibody anti-TH (1:800; Santa Cruz Biotechnol-
ogy) or a mouse monoclonal antibody anti-TH (1:700; Millipore,
Billerica, MA), together with a mouse monoclonal antibody to p-
ERK1/2 (1:400; Cell Signaling Technology, Beverly, MA) or a rabbit
polyclonal antibody to p-Akt(Thr308) (1:400; Cell Signaling Technol-
ogy), respectively. To investigate the expression of Thr-389 phosphor-
ylated p70 ribosomal S6 protein kinase (p-p70S6K), a mouse
monoclonal antibody anti- p-p70S6K (1:500; Cell Signaling Technol-
ogy) was used together with the rabbit polyclonal antibody anti-TH.
Alexa Fluor 488- and Cy3-conjugated secondary antibodies (Jackson
ImmunoResearch) were used. As negative control, cultured neurons
were incubated with the secondary antibodies only. Each experiment
was repeated three times, and all dopaminergic neurons present in
two coverslides for each treatment condition were assessed. Immuno-
fluorescences for p-ERK1/2 and p-Akt(Thr308) were visualized using an
Olympus IX51 microscope (Hamburg, Germany), and TH- immuno-
reactivity (IR) neurons immunostained for p-p70S6K were analyzed
using a Zeiss LSM 510 Meta confocal microscope equipped with Plan-
Apochromat 63/1.4 numerical aperture oil objective and LSM 510
Meta Software, version 3.5 (Carl Zeiss AG, Oberkochen, Germany).
Confocal digital images were further examined using the Axio Vision
Release, version 4.8.2, software (Carl Zeiss AG).
Immunohistochemistry of Brain Sections. Newborn mice
were sacrificed at P1, and brain was removed, fixed overnight in
PBS 4% paraformaldehyde, cryoprotected in 20% sucrose, and rapidly
frozen by immersion in isopentane on dry ice. For each brain, a com-
plete set of coronal sections was cut through the SN and VTA at 30 mm.
Sections were mounted on slides, blocked, and permeabilized with
PBS, 5% BSA (Sigma-Aldrich), and 0.1% Triton (Sigma-Aldrich) for
30 minutes at room temperature. They were incubated with the rabbit
anti-TH antibody (1:500; Santa Cruz Biotechnology) diluted in PBS and
1% BSA overnight at 4°C. Then, they were washed and incubated with
a biotinylated goat anti-rabbit antibody (Jackson ImmunoResearch)
diluted in PBS and 1% BSA for 30 minutes at room temperature,
followed by the ABComplex and development with 3,39-diaminoben-
zidine (DAB).
Computer-Assisted Morphologic Analysis. Digital images
from primary neuronal cultures or mesencephalic brain tissues were
acquired with an Olympus IX51 microscope connected to an Olympus
digital camera and a PC. Morphometric measurements were performed
by a blinded examiner on digitalized images using Image-Pro Plus
software (Media Cybernetics, Bethesda, MD). For in vitro primary
neuronal culture, the morphologic indicators of structural plasticity
were (i) the maximal dendrite length, (ii) the number of primary
dendrites, and (iii) the soma area (Schmidt et al., 1996). Maximal
dendrite lengthwas defined as the distance from the soma (hillock base)
to the tip of the longest dendrite for each neuron; dendrites shorter than
20 mm were excluded from the analysis. Primary dendrites were
defined as those directly stemming from the soma. Soma area was
assessed by measuring the surface (mm2) included by the external
perimeter drawn on the cell membrane of neurons identified by TH-IR
staining. Two coverslides per treatment group were examined to obtain
measurements from at least 30 neurons. For ex vivo studies, computer-
assistedmorphometry was performed as described inCollo et al. (2012).
The effects of nicotine on newborn mice were assessed by measuring in
each brain the soma area of 90–120 dopaminergic neurons at various
rostrocaudal levels of SN andVTA, respectively. The same rostrocaudal
levels were considered in each treatment group to keep anatomic
variance partially controlled. In a typical experiment, eight newborn
mice from three different mothers per group were included. The soma
area of dopaminergic neurons on histologic preparations was measured
as described for TH-IR primary neurons in cultures.
Western Blotting. Western blotting was performed at different
time points (1–10 minutes) after challenge with nicotine (10 mM) and/
or after pretreatments with either D3R antagonist SB-277011-A
(50 nM) or phosphatidylinositol-3-kinase (PI3K) antagonist LY294002
(10 mM). For studies in D3KO and singenic wild-type mice, challenges
were produced with nicotine (10 mM) and 7-OH-DPAT (50 nM).
Mesencephalic cultures were washed with ice-cold PBS and lysed in
a buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 1% Igepal, 1 mM po-
lymethanesulphonyl fluoride, and complete protease inhibitors (Roche
Diagnostics, Mannhein, Germany) for 10 minutes in ice. Neurons were
homogenized with a probe-type sonicator on ice and centrifuged at
13,000g for 10 minutes at 4°C. The protein concentration was
measured using a DC-protein assay (Bio-Rad, Hercules, CA). Twenty
micrograms of total proteins were resolved by 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and blotted onto a poly-
vinylidene difluoride membrane (Immobilon-P; Millipore). Mem-
branes were blocked in Tris-buffered saline/Tween 20 (TBST; 25 mM
Tris base, 137 mM NaCl, 2.7 mM KCl and 0.1% Tween-20, pH 7.6)
and 5% dry milk and incubated overnight with the primary antibody
diluted in 5% BSA in TBST. The primary antibodies used were anti-
p-ERK1/2 (1:1000) and anti-ERK1/2 (1:1000) mouse monoclonal
antibodies (both from Santa Cruz Biotechnology); anti-p-Akt(Thr308)
(1:2000) rabbit polyclonal antibody; anti-Akt (1:1000) rabbit poly-
clonal antibody; anti-p-p70S6K (1:2000) and anti-p70S6K (1:2000)
mouse monoclonal antibodies (all from Cell Signaling Technology);
anti-TH (1:1000) rabbit polyclonal antibody (Millipore); and anti-
a-Tubulin (1:20000) mouse monoclonal antibody (Sigma-Aldrich). In
a typical experiment, the same membrane was processed in the
following order: incubation with anti-p-ERK1/2 antibody, stripping
with the Re-Blot Plus Strong Solution (Millipore), incubation with
anti-ERK1/2 antibody, incubation with anti-TH antibody, and incu-
bation with anti-a-Tubulin antibody. An equivalent protocol was
performed for p-Akt and p-p70S6K blotting. After the incubation
with primary antibodies, blots were washed in TBST, incubated with
appropriate horseradish peroxidase–conjugated secondary antibod-
ies (goat anti-rabbit or goat anti-mouse; Santa Cruz Biotechnology),
and developed using a chemiluminescent substrate (ECL, LiteAblot
Extend; EuroClone). Specific bands were analyzed by densitometric
scanning of exposed film using Gel-pro analyzer software (Media
Cybernetics). In each experiment, the specific signal of p-ERK1/2,
p-Akt, and p-p70S6K proteins was normalized to the corresponding
ERK1/2, Akt, or p70S6K signals, respectively, and then to the level
of TH and a-Tubulin measured in the same preparation.
Statistical Analysis. Data were expressed as mean 6 S.E.M. if
not stated otherwise. Significant differences from control conditions
were determined using either one-way or two-way analysis of vari-
ance, followed by a posteriori Bonferroni’s test formultiple comparisons
provided by GraphPad Prism, version 4.0 for Windows (GraphPad
Software, San Diego, CA).
Results
Nicotine-Induced Structural Plasticity in Primary
Cultures of Mesencephalic DAergic Neurons. Mesence-
phalic DAergic neurons were visualized using a TH antibody
as shown in Fig. 1, A and B. The time- and dose-dependency of
nicotine effects on structural plasticity measured as maximal
dendrite length, number of primary dendrites, and cell body
size are shown in Fig. 1, C–E. Various doses of nicotine (0.1, 1,
and 10 mM) or vehicle were used, and their effects on neuronal
cultures were seen at two different time points: 24 hours and
72 hours. The maximal length of dendrites showed a signifi-
cant treatment effect [F(3,232) 5 54.32; P , 0.0001], with
significant difference from vehicle already at 1 mM nicotine
and stronger effect at 10 mM nicotine (Bonferroni’s test P ,
0.001 versus vehicle). This effect was more marked at 72
hours, as indicated by the significant time effect [F(1,232) 5
9.28; P , 0.001], while the treatment  time interaction was
not significant (Fig. 1C). The analysis of number of pri-
mary dendrites indicated a dose-related treatment effect
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[F(3,344)5141.7, P , 0.0001], with significant differences
between each dose (Bonferroni’s test P , 0.001) and
a significant time effect [F(1,344) 5 17.53; P , 0.0001] with
the strongest signal at 72 hours (Bonferroni’s test P , 0.01).
Again, the treatment  time interaction was not significant.
The analysis of the cell soma area showed significant treatment
effect [F(3,232)56.19;P, 0.0005] and time effect [F(1,232)557.01;
P , 0.0001], with a treatment  time interaction that was
highly significant [F(1,3) 5 7.20; P , 0.0001]. Post-hoc
analysis showed that lack of effects at 24 hours versus
baseline was associated with a strong growth at 72 hours, an
effect that showed clear dose-dependency (Fig. 1E). In one
independent series of experiments, when the dose of 10 mM
nicotine was incubated for 10 minutes, 1 hour, 6 hours, 12
hours, 24 hours, and 72 hours, significant difference from
vehicle of dendrite length, number, and soma area were
observed starting at 12 hours, progressively increasing with
a peak at 72 hours (unpublished data). On the basis of these
observations, the nicotine dose of 10 mM and an incubation
time of 72 hours were chosen for further studies.
Nicotine-Induced Structural Plasticity Depends on
a4b2* nAChRs: Pharmacological and KO Mouse Stud-
ies. The involvement of nAChRs in nicotine-induced struc-
tural plasticity of mesencephalic DAergic neurons was tested
in independent experiments after pretreatments with the
nonselective nAChR antagonist mecamylamine (MEC), the
selective b2* nAChR antagonist DHbΕ, and the selective a7
nAChR antagonist MLA (Fig. 2, A–C). The maximal dendrite
length showed a significant treatment effect [F(7,232) 5
17.58; P , 0.0001], with nicotine producing a significant
increase (Bonferroni’s test P , 0.001), and this effect was
significantly attenuated by MEC or DHbE (Bonferroni’s
test P , 0.01), but not by MLA; incubation with nAChR
antagonists alone (i.e., when vehicle was added instead of
nicotine) showed no difference from vehicle (Fig. 2A). Similar
significant effects of treatment were observed for the number
of primary dendrites [F(7,471) 5 9.69; P , 0.0001] (Fig. 2B),
and for the soma area [F(7, 392) 5 12.66; P , 0.0001]
(Fig. 2C), the increase produced by nicotine (Bonferroni’s test
P , 0.001) was significantly attenuated by MEC or DHbE
(Bonferroni’s test P , 0.01) but not by MLA, whereas no dif-
ference was observed when the nAChR antagonists were
given alone. Overall, these data indicate the involvement of
b2* nAChR and excluded the involvement of a7* nAChR.
Because the most common b2* nAChR expressed in DAergic
neurons is the a4b2* nAChR (Champtiaux et al., 2003; Zhao-
Shea et al., 2011), we extended these observations with use of
cultures of mesencephalic neurons obtained from a4 nAChR
KO (a4KO) mice. Structural plasticity was tested by adding
nicotine (10 mM), 7-OH-DPAT (5 nM), and BDNF (10 ng/ml) to
the incubation media 72 hours before morphologic assess-
ment. The D3R agonist 7-OH-DPAT (5 nM) was included
because we previously showed a reliable neurotrophic-like
effect in the same mesencephalic preparation (Collo et al.,
2008), whereas BDNF is a well-known neurotrophic factor for
DAergic neurons (Hyman et al., 1991). In this experiment,
cultures from a4KO mice were compared with cultures from
wild-type mice. Maximal dendrite length of DAergic neurons
isolated from a4KO mouse embryos was significantly in-
creased by BDNF and by 7-OH-DPAT (Bonferroni’s test P ,
0.001), but not by nicotine, at variance with what was obtained
in wild-type mice that responded significantly to all treat-
ments (Bonferroni’s test P , 0.01; or P , 0.001) (Fig. 2D).
The number of primary dendrites in response to treatments
was also significantly affected by the a4KO genotype (Fig. 2E).
Cultures prepared from a4KOmice responded significantly to
7-OH-DPAT and BDNF (Bonferroni’s test P , 0.05; or P ,
0.01) but were not affected by nicotine, whereas in cultures
Fig. 1. Morphologic effects of nicotine on
mesencephalic dopaminergic neurons. (A and
B) Representative photomicrographs of TH-IR
neurons after 72 hours exposure to vehicle (A)
or 10 mM nicotine (B). Scale bar: 60 mm. (C–E)
Dose-response curve and time-dependence of
morphologic effects of nicotine on maximal
dendrite length (C), number of primary den-
drites (D), and soma area (E) measured 24
hours (continuous line) or 72 hours (dotted
line) after treatment (0 = vehicle). In all
panels, values are represented as mean 6
S.E.M. (***P , 0.001; **P , 0.01; *P , 0.05
versus vehicle, post-hoc Bonferroni’s test).
Nicotine-Induced Structural Plasticity in DA Neurons 1179
prepared from wild-type mice, all treatments were effective
(Bonferroni’s test P , 0.05; or P , 0.01). Similar results were
obtained when measuring the soma areas (Fig. 2F).
Overall, this study indicates that neurons carrying a4
nAChR null mutation are still capable of responding to
neurotrophic stimuli, but not to nicotine, indicating a critical
role of the a4b2* nAChR in the structural plasticity produced
by nicotine.
Nicotine-Induced Structural Plasticity Depends on
Dopaminergic D3R: Pharmacological and D3KOMouse
Studies. To test this hypothesis, the involvement of dopa-
mine receptors in nicotine-induced structural plasticity of
mesencephalic dopaminergic neurons was assessed using
pretreatments with the D1R antagonist SCH23390 (1 mM),
the D2⁄D3R antagonist sulpiride (5 mM), or the D3R an-
tagonist SB-277011-A (50 nM) added to the cultures 20
minutes before nicotine (10 mM) and studied after 72 hours.
The maximal dendrite length was significantly affected by the
treatment [F(7,279) 5 13.29; P , 0.0001], with the nicotine-
induced increase (Bonferroni’s test P , 0.001) significantly
attenuated by sulpiride (Bonferroni’s test P , 0.01) and by
SB-277011-A (Bonferroni’s test P , 0.001), but not by
SCH23390, whereas incubation with dopamine antagonists
alone, when vehicle was added instead of nicotine, showed no
difference (Fig. 3A). Analogous results were obtained by
measuring the number of primary dendrites, with a significant
treatment effect [F(7,383) 5 10.28; P , 0.0001]; the nicotine-
induced increase (Bonferroni’s test P , 0.001) was attenuated
by sulpiride (Bonferroni’s test P , 0.001) or SB-277011-A
(Bonferroni’s test P , 0.001), but not by SCH23390 (Fig. 3B).
The soma area was also affected by the treatments [F(7,399)5
9.79; P , 0.0001] in the same way described for maximal
dendrite length and number of primary dendrites (Fig. 3C).
These data support a critical role for D3R in mediating the
nicotine effects on dopaminergic neuron structure.
The critical role of D3 receptors suggested by these phar-
macologic observations was confirmed using mesencephalic
neurons obtained from D3KO mice and compared with pri-
mary neurons from singenic wild-type mice. Structural plas-
ticity was assessed 72 hours after incubation with nicotine
Fig. 2. Involvement of nicotinic acetylcholine receptor subtypes in morphologic effects of nicotine on mesencephalic dopaminergic neurons studied 72
hours after treatment. (A–C) Representative experiment of the effects of nAChR antagonists methyllycaconitine (200 nM), mecamylamine (100 mM),
dihydro-b-erytroidine (10 mM), or vehicle added 20 minutes before nicotine (10 mM) onmaximal dendrite length, number of primary dendrites, and soma
area. (D–F) Morphologic effects of nicotine on TH-IR neurons from wild-type and a4KO mice 72 hours after treatment expressed as mean values.
Mesencephalic neurons were exposed to nicotine (10 mM), 7-OH-DPAT (5 nM), or BDNF (10 ng/ml), and the following end points were measured:
maximal dendrite length (D), number of primary dendrites (E), and soma area (F). Experiments were replicated three times. Values are represented as
mean6 S.E.M. (***P, 0.001 versus vehicle; **P, 0.01 versus vehicle; *P, 0.05 versus vehicle; oooP, 0.001 versus nicotine; ooP, 0.01 versus nicotine;
post-hoc Bonferroni’s test).
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(10 mM), the D3R agonist 7-OH-DPAT (5 nM), the neurotrophic
factor BDNF (10 ng/ml), or vehicle. Maximal dendrite length
was significantly affected by genotype, showing that cultures
prepared from wild-type mice responded significantly to
nicotine, 7-OH-DPAT, or BDNF (Bonferroni’s test P , 0.001),
whereas cultures prepared from D3KO mice responded sig-
nificantly only to BDNF (Bonferroni’s testP, 0.001), but not to
nicotine or 7-OH-DPAT (Fig. 3A). The number of primary
dendrites and soma size were also significantly affected by
genotype, showing that, in cultures prepared from wild-type
mice, nicotine, BDNF, and 7-OH-DPAT increased the number
of primary dendrites (Bonferroni’s test P , 0.001), whereas
cultures prepared from D3KO mice significantly responded
only to BDNF (Bonferroni’s test P , 0.001), but not to nicotine
or 7-OH-DPAT (Fig. 3, B and C). Overall, this study indicates
that neurons carrying a D3R null mutation are still capable
of responding to neurotrophic stimuli conveyed by BDNF, but
not to those of nicotine and 7-OH-DPAT effects, suggesting a
necessary role for D3R in mediating nicotine effects.
Nicotine Exposure in Pregnant Mothers Produced
Structural Plasticity in Mesencephalic Neurons of the
Offspring: Lack of the Effects in D3KOMice. The in vivo
relevance of the nicotine-induced changes observed in cul-
tured mesencephalic dopaminergic neurons dissected from
the E12.5 mouse embryo was investigated by repeatedly
exposing mouse embryos to nicotine while in uterus from
E12.5 through E17. Treatments were performed in both wild-
type and D3KO pregnant mice, and effects on soma area
were measured on the mesencephalon of newborns (Fig. 4, A
and B). Two-way analysis of variance was used to assess the
genotype treatment effects and interactions. The analysis of
soma area in the VTA showed a significant genotype effect
[F(1,28)5 33.23;P, 0.0001], treatment effect [F(1,28)5 25.86;
P , 0.0001], and interaction [F(1,28)5 14.44; P , 0.005], with
post-hoc test showing effect of nicotine only in wild-type mice
(P, 0.001) (Fig. 4C). Soma area in the SN showed a significant
genotype effect [F(1,28) 5 29.42; P , 0.0001], treatment effect
[F(1,28)5 19.50; P, 0.0005], and interaction [F(1,28)5 19.40;
P, 0.001], with post-hoc test showing effect of nicotine only in
wild-type mice (P , 0.001) (Fig. 4D).
Nicotine-Induced Activation of the Intracellular
ERK and Akt-mTOR Pathways in Primary Dopaminer-
gic Neurons Is Mediated by D3R. The effect of nicotine on
ERK1/2 phosphorylation was investigated by challenging
Fig. 3. Involvement of dopamine D3 receptor in morphologic effects of nicotine on mesencephalic dopaminergic neurons studied 72 hours after
treatment. (A–C) Pharmacological studies of the effects of dopamine antagonists SCH23390 (1 mM), sulpiride (5 mM), SB-277011-A (50 nM), or vehicle
added 20 minutes before nicotine (10 mM) to the primary cultures of mesencephalic neurons on maximal dendrite length, number of primary dendrites,
and soma area. (D–F)Morphologic effects of nicotine on TH-IR neurons fromwild-type and D3KOmice 72 hours after treatment. Mesencephalic neurons
were exposed to nicotine (10 mM), 7-OH-DPAT (5 nM), or BDNF (10 ng/ml), and the following end points were measured: maximal dendrite length (D),
number of primary dendrites (E), and soma area (F). In all panels, values are represented as mean6 S.E.M. (***P, 0.001; **P, 0.01; versus vehicle;
°°°P , 0.001; °°P , 0.01; °P , 0.05 versus nicotine; post-hoc Bonferroni’s test).
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mesencephalic neurons in culture with 10 mM nicotine.
Western blot analysis over time showed an increase of
p-ERK1/2 [F(4,23)5 7.63; P , 0.001], with a significant peak
activity versus vehicle at 2 minutes (Bonferroni’s test P ,
0.01) (Fig. 5A). Incubation with SB-277011-A (50 nM) 20
minutes before challenge significantly attenuated the p-ERK1/2
peak increase [F(3,15) 5 8.91; P , 0.005], providing evidence
of D3R involvement. No effect on p-ERK1/2 was produced by
SB-277011-A when tested alone (Fig. 5B). Moreover, 20
minutes pretreatment with the PI3K inhibitor LY294002
(10mM) significantly antagonized the peak increase of p-ERK1/2
levels [F(3,27) 5 12.41; P , 0.0001], whereas no effects on
ERK1/2 phosphorylation were observed when LY294002 was
tested alone (Fig. 5C). Similar results were obtained in
parallel experiments using double-staining immunofluores-
cence aimed to localize the expression of p-ERK1/2 in
dopaminergic neurons. Nicotine activated p-ERK in TH-IR
neurons (Fig. 5, D–F), and its effect was blocked by pre-
treatment with either SB-277011-A (Fig. 5, G–I) or LY294002
(Fig. 5, M–O). In control experiments, incubation with either
SB-277011-A (Fig. 5, J–L) or LY294002 (Fig. 5, P–R) alone did
not affect p-ERK1/2 expression.
Mesencephalic neurons obtained from embryos of D3KO
and singenic wild-type mice were processed in separated
cultures in the same experiment. The effects of either nicotine
(10 mM) or 7-OH-DPAT (50 nM) on ERK1/2 phosphorylation
were investigated by Western blot analysis 2 minutes after
treatment. Nicotine and 7-OH-DPAT significantly increased
p-ERK1/2 in wild-type mice [F(2,24) 5 5.68; P , 0.01] but not
in D3KO mice, as indicated by the highly significant in-
teraction [F(2,24) 5 13.60; P , 0.0001] and genotype effect
[F(1,24) 5 46.40; P , 0.0001] obtained with two-way analysis
of variance (Fig. 5S).
The effect of nicotine on Akt phosphorylation was investi-
gated by challenging mesencephalic neurons with 10 mM
nicotine. Western blot analysis showed a rapid increase in Akt
phosphorylation [F(4,27) 5 9.03; P , 0.0002], reaching the
peak activity at 1 minute exposure (Bonferroni’s test P , 0.01)
(Fig. 6A). Incubation with SB-277011-A (50 nM) 20 minutes
before challenge significantly attenuated the increase of Akt
phosphorylation produced by nicotine [F(3,19) 5 8.40; P ,
0.002] (Fig. 6B). Moreover, 20 minutes pretreatment with
LY294002 (10 mM) antagonized the significant increase of p-
Akt levels [F(3,19)5 7.91; P, 0.002] (Fig. 6C). Similar results
were obtained in parallel experiments using double-staining
immunofluorescence aimed to localize the expression of p-Akt-
IR in dopaminergic neurons. Nicotine activated p-Akt in TH-IR
neurons (Fig. 6, D–F), whereas its effect was blocked by
pretreatment with either SB-277011-A (Fig. 6, G–I) or
LY294002 (Fig. 6, M–O). In control experiments, incubation
with either SB-277011-A (Fig. 6, J–L) or LY294002 (Fig. 6,
P–R) alone did not affect p-Akt expression. Mesencephalic
neurons obtained from embryos of D3KO and singenic wild-
type mice were processed in separated cultures in the same
experiment. Increase of p-Akt was produced by nicotine and
7-OH-DPAT in cultures from wild-type mice but not in D3KO
mice, as indicated by the highly significant interaction [F(2,24)5
15.73; P , 0.02] and genotype effect [F(1,24) 5 26.10; P ,
0.0001] obtained with two-way analysis of variance (Fig. 6S).
The effect of nicotine on p70S6K phosphorylation, one of
the main substrates of the activated mammalian target of
rapamycin complex 1 (mTORC1), was investigated by chal-
lenging mesencephalic neurons with 10 mM nicotine. Western
blot analysis showed a delayed increase of p70S6K phosphor-
ylation [F(4,21) 5 8.00; P , 0.001] that reached the peak
activity at 5 minutes exposure (Bonferroni’s test P , 0.001)
(Fig. 7A). Incubation with SB-277011-A (50 nM) 20 minutes
before challenge significantly attenuated the increase of
p70S6K phosphorylation produced by nicotine [F(3,21) 5 7.61;
P , 0.002] (Fig. 7B). Moreover, 20 minutes pretreatment with
LY294002 (10 mM) antagonized the increase of p-p70S6K levels
[F(3,21) 5 10.03; P , 0.0005] (Fig. 7C).
Information about colocalization of p-p70S6K-IR in TH-IR
neurons after nicotine was obtained in parallel experiments
using confocal microscopy (Fig. 7, D–L). Nicotine activated p-
p70S6K-IR in TH-IR neurons (Fig. 7D). Confocal recon-
structed TH-IR dendrites visualized with different angles
confirmed the presence of p-p70S6K-IR and TH-IR in the
same structures (Fig. 7, E and F). Of interest, p-p70S6K-IR
and TH-IR showed only a partial overlap of IR, suggesting
localization in different dendrite microdomains (Fig. 7, E and
F). No p-p70S6K-IR was observed in TH-IR neurons and
dendrites when the treatment was vehicle (Fig. 7, G and H) or
following nicotine after 20 minutes pretreatment with SB-
277011-A (Fig. 7, I and J) or LY294002 (Fig. 7, K and L),
confirming the data obtained with Western blot.
Nicotine-Induced Structural Plasticity Is Blocked
by Inhibition of the D3R Intracellular Signaling Path-
ways. The involvement of phosphokinases that mediate the
activation of the ERK1/2, Akt, and mTORC1 intracellular
pathways in determining nicotine-induced long term structural
Fig. 4. Effects of prenatal nicotine exposure on structural plasticity of
dopaminergic neurons of wild-type and D3KO newborn mice. (A)
Representative low-magnification photomicrograph of a coronal brain
section of a P1 mouse exposed to daily treatment with nicotine intra-
peritoneally (5 mg/kg/die) in utero from E12.5 through E17. Sections were
immunostained with anti-TH antibody to identify dopaminergic neurons
in VTA and SN. (B) High magnification of TH-IR dopaminergic neurons
from VTA, in which soma area was investigated. (C and D) Nicotine effects
on the soma area of TH-IR neurons in the VTA and SN, respectively, of
wild-type and D3KOmice. In all panels, values are represented as mean6
S.E.M. (***P , 0.001 versus saline; post-hoc Bonferroni’s test). Scale bar:
60 mm.
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plasticity of mesencephalic dopaminergic neurons was tested
in independent experiments. Nicotine (10 mM) was adminis-
tered after pretreatments with the pharmacologic inhibitors
LY294002 (10 mM), rapamycin (2 nM), or PD98059 (10 mM),
which block phosphorylation of PI3K, mTORC1, and mitogen-
activated protein kinase kinase (MEK), respectively. Three
days later, maximal dendrite length showed a significant
treatment effect, mostly because of a reliable increase produced
by nicotine (Bonferroni’s test P, 0.001) that was attenuated in
various experiments by pretreatment with either LY294002
[F(3,127) 5 7.30; P , 0.0002; Bonferroni’s test P , 0.01]
(Fig. 8A), rapamycin [F(3,159)5 8.71; P, 0.0001; Bonferroni’s
test P , 0.01] (Fig. 8D), or PD98059 [F(3,123) 5 9.10; P ,
0.0001; Bonferroni’s test P , 0.01] (Fig. 8G).
Similar significant outcomes were observed for the number
of primary dendrites; the enhancing effects of nicotine
(Bonferroni’s test P , 0.01) were blocked by pretreatments with
LY294002 [F(3,122)5 6.11;P, 0.001; Bonferroni’s testP, 0.01]
(Fig. 8B), rapamycin [F(3,199) 5 5.67; P , 0.001; Bonferroni’s
testP, 0.05] (Fig. 8E), andPD98059 [F(3,119)5 5.66;P, 0.002;
Fig. 5. ERK1/2 phosphorylation activated by nicotine challenge in mesencephalic TH-IR neurons is prevented by D3R antagonist SB-277011-A and
PI3K inhibitor LY294002 and is blocked in D3KOmice. (A) Representative time course of ERK1/2 phosphorylation induced by nicotine (10 mM) at 0, 1, 2,
5, and 10 minutes; cell lysates were processed for Western blot analysis that was performed using antibodies to detect pERK1/2, ERK1/2, TH, and
tubulin levels; membranes were stripped and reprobed as described inMaterials and Methods. Right panel, densitometric analysis of blots (n = 6) with
specific levels of p-ERK1/2 normalized to the corresponding ERK1/2, TH, and tubulin levels. (B) Representative blot showing the effects of SB-277011-A
(50 nM) added to the cultures 20minutes before challenge with nicotine (10mM) assessed after 2minutes. Right panel, densitometric analysis of blots (n = 6)
normalized as described. (C) Representative blot showing the effects of LY294002 (10 mM) added to the cultures 20 minutes before challenge with nicotine
(10mM) assessed after 2minutes. Right panel, densitometric analysis of blots (n = 6) normalized as described. (D–R) Immunofluorescencemicrophotographs
of TH-IR (D, G, J,M, and P), p-ERK-IR (E, H,K,N, andQ), and their colocalization (F, I, L, O, and R) inmesencephalic dopaminergic neurons 2minutes after
treatment with nicotine (D–F) and SB-277011-A (20minutes), followed by nicotine (G–I), SB-277011-A alone (J–L), and LY294002, followed by nicotine (M–
O) or LY294002 alone (P–R). Cell nuclei were stained with Hoechst. Scale bar: 20 mm. (S) Representative blot showing the effects of vehicle, nicotine, and
7-OH-DPAT on p-ERK1/2 in mesencephalic cultures from wild-type and D3KO mice. Right panel, densitometric analysis of blots (n = 4) normalized
as described. V, vehicle; N, nicotine; SB, SB-277011-A; Ly, LY294002; 7OH, 7-OH-DPAT. Densitometric values were represented as percentage of
vehicle or nicotine values as mean 6 S.E.M. (***P , 0.001; **P , 0.01; *P , 0.05 versus vehicle; oooP , 0.001; ooP , 0.01 versus nicotine post-hoc
Bonferroni test).
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Bonferroni’s test P , 0.05] (Fig. 8H). The same pattern
was observed by measuring the changes in TH-IR soma area,
with increments produced by nicotine (Bonferroni’s test P ,
0.01) that were antagonized by pretreatment with LY294002
[F(3, 141) 5 10.86; P , 0.0001; Bonferroni’s test P , 0.001]
(Fig. 8C), rapamycin [F(3,159)5 7.23; P, 0.0001; Bonferroni’s
test P , 0.01] (Fig. 8F), and PD98059 [F(3, 137) 5 6.01; P ,
0.001; Bonferroni’s test P , 0.05] (Fig. 8I).
Overall, these data suggest that both the PI3K-Akt-mTORC1
and the PI3K-MEK-ERK signaling pathways are necessary to
mediate the structural plasticity effects induced by nicotine in
mesencephalic dopaminergic neurons.
Discussion
In the present study, we showed that prolonged exposure to
nicotine produced structural plasticity in mesencephalic
DAergic neurons of the mouse embryo by increasing soma
area and dendrite arborisation via a mechanism dependent
on D3R activation by engaging of ERK and Akt-mTOR sig-
naling pathways. These findings support evidence of nicotine-
dependent structural plasticity in the DAergic system (Janson
et al., 1988a,b; Bunnemann et al., 2000; Mudo et al., 2007) and
clarify the role of specific intracellular pathways involved in
growth and survival (Doura et al., 2010; Quik et al., 2012). In
our work, nicotine produced structural changes in DAergic
Fig. 6. Akt phosphorylation activated by nicotine challenge in mesencephalic TH-IR neurons is prevented by D3R antagonist SB-277011-A and PI3K
inhibitor LY294002 and is blocked in D3KOmice. (A) Representative time course of Akt phosphorylation induced by nicotine (10 mM) at 0, 1, 2, 5, and 10
minutes; cell lysates were processed for Western blot analysis that was performed using antibodies to detect pAkt, Akt, TH, and tubulin levels;
membranes were stripped and reprobed as described inMaterials and Methods. Right panel, densitometric analysis of blots (n = 6) with specific levels of
p-Akt normalized to the corresponding Akt, TH, and tubulin levels. (B) Representative blot showing the effects of SB-277011-A (50 nM) added to the
cultures 20 minutes before challenge with nicotine (10 mM) assessed after 1 minute. Right panel, densitometric analysis of blots (n = 5) normalized as
described. (C) Representative blot showing the effects of LY294002 (10 mM) added to the cultures 20 minutes before challenge with nicotine (10 mM)
assessed after 1 minute. Right panel, densitometric analysis of blots (n = 5) normalized as described. (D–R) Immunofluorescence microphotographs of
TH-IR (D, G, J, M, and P), p-Akt-IR (E, H, K, N, and Q), and their colocalization (F, I, L, O, and R) in mesencephalic dopaminergic neurons 1 minute after
treatment with nicotine (D–F), SB-277011-A (20 minute) followed by nicotine (G–I), SB-277011-A alone (J–L), LY294002 followed by nicotine (M–O), and
LY294002 alone (P–R). Cell nuclei were stained by Hoechst. Scale bar: 20 mm. (S) Representative blot showing the effects of vehicle, nicotine, and 7-OH-
DPAT on p-Akt in mesencephalic cultures fromwild-type and D3KOmice. Right panel, densitometric analysis of blots (n = 3) normalized as described. V,
vehicle; N, nicotine; SB, SB-277011-A; Ly, LY294002; 7OH, 7-OH-DPAT. Densitometric values were represented as percentage of vehicle or nicotine
values as mean 6 S.E.M. (**P , 0.01; *P , 0.05 versus vehicle; ooP , 0.01; °P , 0.05 versus nicotine post-hoc Bonferroni test).
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neurons either when added to primary cultures obtained from
the mesencephalon of E12.5 mouse embryos or when admin-
istered to pregnant mice at about the same stage of embryo
development and studied in the VTA and SN of P1 offspring.
In vitro studies in primary neurons were conducted using
a validated protocol that generates almost pure neuronal
cultures containing 5–7% dopaminergic neurons and less than
0.5% astrocytes (Collo et al., 2008). Nicotine produced a dose-
dependent effect on maximal dendrite length and on the
number of primary dendrites starting at the dose of 1 mM,
levels observed in smokers and compatible with in vivo
pharmacologic effects in mice (Changeux, 2010). In the present
work, we chose to use the dose of 10 mM to maximize the
pharmacological signal of the test. This effect was detectable at
12–24 hours and stabilized to the highest value at 72 hours of
incubation. The delayed effect on neuronal soma was also
observed after cocaine exposure (Collo et al., 2012), a phenom-
enon probably related to the soma geometry and/or to specific
molecular substrates engaged in growth (Scheidenhelm et al.,
2005; Russo et al., 2010). The involvement of a4b2* nAChR
in mediating nicotine’s effects was supported by the blockade
of dendrite and soma growth produced by the nonselective
antagonist MEC and by the b2*2selective antagonist DHbE,
whereas no effects were observed with the a7 nAChR an-
tagonist MLA. This argument is further supported by the lack
of response to nicotine of primary cultures from embryos of
Fig. 7. p70S6K phosphorylation activated
by nicotine challenge in mesencephalic TH-
IR neurons is prevented by D3R antagonist
SB-277011-A and PI3K inhibitor LY294002.
(A) Time course of p70S6K phosphorylation
induced by nicotine (10 mM) at 0, 2, 5, 10,
and 30 minutes; upper panel, densitometric
analysis of blots (n = 5) with specific levels
of p-p70S6K, normalized to the correspond-
ing p70S6K, TH, and tubulin levels; lower
panel representative Western blot; cell
lysates were processed for Western blot
analysis that was performed using anti-
bodies to detect p-p70S6K, p70S6K, TH,
and tubulin levels; membranes were strip-
ped and reprobed as described inMaterials
and Methods. (B) Effect of SB-277011-A
(50 nM) added to the cultures 20 minutes
before challenge with nicotine (10 mM) as-
sessed after 5 minutes; upper panel, densi-
tometric analysis of blots (n = 6) normalized
as described; lower panel, representative
Western blot. (C) Effects of LY294002
(10 mM) added to the cultures 20 minutes
before challenge with nicotine (10 mM)
assessed after 5 minutes; upper panel, den-
sitometric analysis of blots (n = 6) normal-
ized as described; lower panel, representative
Western blot. Densitometric values were
represented as percentage of vehicle or
nicotine values as mean 6 S.E.M. (***P ,
0.001; **P , 0.01 versus vehicle; ooP ,
0.01 versus nicotine post-hoc Bonferroni test);
V, vehicle; N, nicotine; SB, SB-277011-A; Ly,
LY294002. (D–F) Confocal analysis of TH-
IR neurons showing that p-p70S6K appears
in the soma and in distinct punctae along
dendrites 5 minutes after nicotine (10 mM)
treatment. p-p70S6K (rabbit polyclonal anti-
p-p70S6K, Cy3-red), TH (mouse monoclonal
anti-TH, Alexa Fluor 488-green). A high
magnification of a representative dendrite
is shown in its Z-stack projection on xy
plane (E) and on yz plane (F). (G–H) TH-IR
neurons treated with vehicle (G) and a
Z-stack projection of a dendrite on xy plane
(H); (I–J) pre-treatment of TH-IR neurons
with SB-277011-A followed by nicotine
(10 mM) (I) and a Z-stack projection of a
dendrite on xy plane (J). (K–L) Pretreat-
ment of TH-IR neurons with LY294002
followed by nicotine (10 mM) (K) and a
Z-stack projection of a dendrite on xy plane
(L). Scale bar: 20mm
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a4KOmice, whereas significant responsewas seenwithBDNF,
suggesting the presence of a normal signaling to neurotrophic
stimuli. The lack of response to nicotine was interpreted as
attributable to the absence of heteromeric a4* nAChR, the
most commonly expressed nAChR in mesencephalic dopami-
nergic neurons (Champtiaux et al., 2003; Marubio et al., 2003)
since early embryonic stages (Zoli et al., 1995). Converging
findings indicate that the a4b2* nAChR participates to the
control of DAergic neuron firing in the VTA and of DA release
from DAergic terminals in ventral striatum (Picciotto et al.,
1998; Wonnacott et al., 2000). These a4b2* nAChR regulatory
effects on the mesencephalic DA system are critically involved
in mediating the reinforcing properties of nicotine (Picciotto
et al., 1998; Marubio et al., 2003; Changeux, 2010), evidence
supported by the effects of the a4b2* nAChR partial agonist
varenicline in humans andmice (Rollema et al., 2009; Reperant
et al., 2010). A role of a4b2* nAChR in PD was recently sug-
gested (Mudo et al., 2007; Quik et al., 2012). For example,
varenicline reduced L-3,4-dihydroxyphenylalanine (L-DOPA)–
induced abnormal involuntary movements in rats with partial
striatal dopamine lesion in a model of PD (Huang et al., 2011).
However, because of the higher response obtained with the
10 mM nicotine dose, with respect to the 1 mM dose, we cannot
exclude the involvement of receptors other than high affinity
non-a7 receptors (Jensen et al., 2005).
The morphologic changes produced by nicotine in primary
cultures of mesencephalic neurons resembled those of am-
phetamine and cocaine (Collo et al., 2008, 2012). In these
Fig. 8. Nicotine-induced structural plasticity in dopami-
nergic neurons is prevented by PI3K inhibitor LY294002,
mTORC1 inhibitor rapamycin, and MEK inhibitor
PD98059. (A–C) Morphologic effects of pretreatment (20
minutes) with LY294002 (10 mM) on structural plasticity
produced by nicotine (10 mM) assessed as (A) maximal
dendrite length, (B) number of primary dendrites, and (C)
soma area. (D–F) Morphologic effects of pretreatment (10
minutes) with rapamycin (10 nM) followed by three
washes and incubation with nicotine (10 mM) dissolved
in fresh medium: (D) maximal dendrite length, (E)
number of primary dendrites, and (F) soma area. (G–I)
Morphologic effects of pretreatment (20 minutes) with
PD98059 (10 mM) followed by nicotine (10 mM): (G)
maximal dendrite length, (H) number of primary den-
drites, and (I) soma area. All measurements were per-
formed after 72 hours. (***P, 0.001; **P, 0.01; *P, 0.05
versus vehicle; oooP , 0.001; ooP , 0.01; oP , 0.05 versus
nicotine; post-hoc Bonferroni test).
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studies, we proposed that the high extracellular DA levels
produced by amphetamine and cocaine were involved in
structural plasticity by activating D3 autoreceptors that
are expressed in all TH-positive neurons of the mesen-
cephalon (Diaz et al., 2000). Indeed, we showed that psy-
chostimulant effects were blocked by a low dose of D3R
antagonist SB-277011-A and did not occur in cultures from
D3KO mice. Structural plasticity was produced by D3R-
preferential agonists, such as 7-OH-DPAT, quinpirole, and
ropinerole, all anti-Parkinsonian agents capable of driving
regeneration of mesencephalic DAergic neurons after damage
in vivo (Van Kampen and Eckman, 2006; Joyce and Millan,
2007).
In the present article, we propose that the activation of the
D3 autoreceptors was also critical for generating nicotine-
dependent structural plasticity and that these effects were
possibly mediated by DA released by nicotine. Accordingly,
nicotine-elicited somatodendritic release of DA in VTA
was described in vitro and in vivo (Rahman et al., 2004;
Kleijn et al., 2011), and preliminary findings using high-
performance liquid chromatography measurements indicated
that DA levels were increased by nicotine in the culture media
of mesencephalic neurons (Collo, unpublished data). This
hypothesis is indirectly supported by the evidence that
nicotine-induced structural plasticity was completely pre-
vented by the D3R-preferential antagonist SB-277011-A and
was absent in mesencephalic cultures prepared from D3KO
embryos, whereas BDNF was still effective. Of note, this
interpretation is compatible with the well-established role of
BDNF in controlling D3 receptor expression (Le Foll et al.,
2005) and suggests a reciprocal positive-feedback relationship
in generating neurotrophic effects. Receptor-receptor interac-
tion between D3R and a4b2* nAChR could also occur, as
suggested by the recently described D3R synergistic in-
teraction with D1R (Fiorentini et al., 2008) and the proposed
dimerization between non-a7* nAChR and D2 autoreceptors
in striatal dopaminergic terminals (Quarta et al., 2007).
However, it is possible that D3R IR expressed in other
neurons of SN and VTA that do not contain DA could mediate
some of these effects by engaging other neurotransmitters
(e.g., glutamate) (Sokoloff et al., 2013).
Similar effects were also observed in vivo by exposing
mouse embryos to nicotine during the late phase of preg-
nancy. We observed that nicotine increased the soma size of
DAergic neurons of both VTA and SN in newborn wild-type
mice. The same treatment did not produce any effect in the
D3KO offspring. These results were in line with those
obtained after prenatal exposure to cocaine (Collo et al.,
2012), suggesting that some commonalities between nicotine
and cocaine in generating structural plasticity of DAergic
neurons can be related to the activation of D3R. Incidentally,
prenatal exposure to nicotine and cocaine in human and
rodents was associated with long-lasting postnatal neurobi-
ological and behavioral effects (Crozatier et al., 2003; Bublitz
and Stroud, 2012).
The intracellular pathways that drive the effects of nicotine
on dendritic growth and soma expansion in DAergic neurons
were investigated in primary mesencephalic cell cultures with
use of Western blot and dual-staining immunofluorescence to
localize phosphorylation events in TH-IR–positive profiles.
Exposure to nicotine induced phosphorylation of ERK and of
Akt within 1–2 minutes, suggesting a rapid triggering of two
of the main signaling pathways involved in dendritic growth
and structural plasticity (Alonso et al., 2004; Jaworski et al.,
2005; Kumar et al., 2005; Scheidenhelm et al., 2005). Both
MEK-ERK and PI3K-Akt-mTOR pathways are known to be
activated by BDNF via Ras acting as common activator
(McAllister et al., 1999). Of interest, transactivation between
IGF1 and D3R was described in transfected CHO cells,
suggesting a possible highjacking of neurotrophin intracellu-
lar signaling (Mannoury la Cour et al., 2011). Previously,
using heterologous transfection of D3R, Cussac et al. (1999)
and, later, Beom et al. (2004) showed that D3Rs phosphory-
late both ERK and PI3K-Akt pathways by engaging PI3K.
This mechanism was recently found in DAergic neurons with
use of direct and indirect DAergic agonists (Collo et al., 2008,
2012). In the present work, we showed that pretreatments
with either the PI3K inhibitor LY294002 or the D3R
antagonist SB-277011-A completely blocked ERK and Akt
phosphorylation induced by nicotine. The effects of nicotine
were not observed in mesencephalic neurons obtained from
D3KOmice, further supporting a key role of D3R activation as
mediator of nicotine effect. Furthermore, for the first time to
our knowledge, we provide evidence that in DAergic neurons
the activation of both pathways is required to trigger the
phosphorylation of p70S6K, preferred substrate of mTORC1
involved in ribosomal biogenesis and protein translation
(Jefferies et al., 1997; Kumar et al., 2005). The peak time of
p70S6K phosphorylation followed that of ERK and Akt,
supporting its downstream position in the signaling cascade.
Confocal microscopy showed that nicotine-induced p-p70S6K
was present in the soma and in micro-domains of the
dendrites of DA neurons that do not contain TH-IR. Phos-
phorylation of p70S6K was prevented by pretreatments
with the selective inhibitor of mTORC1 rapamycin (Jefferies
et al., 1997; Jaworski et al., 2005). These findings are in line
with the early observation of dendritic micro-domain activa-
tion of p70S6K induced by N-methyl-D-aspartate in hippo-
campal neurons (Cammalleri et al., 2003). The present data
strongly support the hypothesis that the observed nicotine-
elicited activation of MEK-ERK and PI3K-Akt-mTOR path-
ways mediates structural plasticity, because rapamycin, the
PI3K inhibitor LY294002, or the MEK inhibitor PD98059
blocked nicotine-induced dendrite growth and soma size
increase.
In conclusion, although the relevance of the present obser-
vations to the influence of nicotine on dopaminergic pathways
and cellular signals in adult neurons remains to be confirmed,
they suggest a crucial role for D3R and Akt-mTOR signaling
in the expression of nicotine-induced structural plasticity in
mesencephalic dopaminergic neurons. As such, they provide a
template for further analysis of the role of nicotinic and dopa-
minergicmechanisms in addiction on the one hand (mesolimbic
dopaminergic neurons) and in neuroprotection and motor
behavior on the other (nigrostriatal pathways). Because recent
positron emission tomography findings indicate that D3R are
particularly enriched in human SN and VTA (Searle et al.,
2010), our findings may suggest novel strategies for the treat-
ment of both addiction and PD.
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